CA2375201C - Crystal of (r)-lansoprazole - Google Patents
Crystal of (r)-lansoprazole Download PDFInfo
- Publication number
- CA2375201C CA2375201C CA2375201A CA2375201A CA2375201C CA 2375201 C CA2375201 C CA 2375201C CA 2375201 A CA2375201 A CA 2375201A CA 2375201 A CA2375201 A CA 2375201A CA 2375201 C CA2375201 C CA 2375201C
- Authority
- CA
- Canada
- Prior art keywords
- crystal
- methyl
- benzimidazole
- pyridinyl
- trifluoroethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Description
26456-213(S) DESCRIPTION
Crystal of. (R)-Lansoprazole TECHNICAL FIELD
The present invention relates to a crystal of a benzimidazole compound showing antiulcer action.
BACKGROUND ART
Crystal of. (R)-Lansoprazole TECHNICAL FIELD
The present invention relates to a crystal of a benzimidazole compound showing antiulcer action.
BACKGROUND ART
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof having an antiulcer action is reported in JP-A-61-50978, etc.
There is a demand for a more stable and excellently absorbable antiulcer agent.
DISCLOSURE OF INVENTION
Having chiral sulfur in the molecular structure thereof , 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole occurs in two kinds of optical isomers . After extensive exploration, the present inventors succeeded in optically resolving and crystallizing the (R)-isomer of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, for the first time found that this crystal serves satisfactorily as a pharmaceutical, made further investigationbased on this finding, and developed the present invention.
Accordingly, the present invention relates to:
[1] a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof;
[2] a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole;
There is a demand for a more stable and excellently absorbable antiulcer agent.
DISCLOSURE OF INVENTION
Having chiral sulfur in the molecular structure thereof , 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole occurs in two kinds of optical isomers . After extensive exploration, the present inventors succeeded in optically resolving and crystallizing the (R)-isomer of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, for the first time found that this crystal serves satisfactorily as a pharmaceutical, made further investigationbased on this finding, and developed the present invention.
Accordingly, the present invention relates to:
[1] a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof;
[2] a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole;
[3] a crystal according to the above [2] wherein the X-ray powder diffraction analysis pattern has characteristic peaks at interplanar spacings (d) of 11. 68, 6. 77 , 5. 84, 5. 73, 4. 43 , 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom;
[4] a pharmaceutical composition which comprises the crystal according to the above [1];
[4] a pharmaceutical composition which comprises the crystal according to the above [1];
[5] a pharmaceutical composition according to the above[4], which is for treating or preventing digestive ulcer;
[6] a method for treating or preventing digestive ulcer in a mammal in need thereof which comprises administering to said mammal an effective amount of the crystal according to the above [1] with a pharmaceutically acceptable excipient, carrier or diluent;
[7] use of the crystal according to the above [1] for manufacturing a pharmaceutical composition for treating or preventing digestive ulcer, and so forth.
The "salt" of "(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof" includes, for example, metal salts, salts with organic bases, salts with basic amino acids, and so forth. Preferred are physiologically acceptable salts.
Metal salts include, for example, alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt, magnesium salt and barium salt. Salts with organic bases include, for example, salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N-dibenzylethylenediamine, etc.
Salts with basic amino acids include, for example, salts with arginine, lysine, etc.
The crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof may be a hydrate or not.
Said "hydrate" includes 0.5 hydrate to 5.0 hydrate.
Among others, 0.5 hydrate, 1.0 hydrate, 1.5 hydrate, 2.0 hydrate and 2.5 hydrate are preferred. More preferred is 1.5 hydrate.
The crystal of .(R)=2-[[[3-methyl-4-(2,2,2-tri.fluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H=
benzimidazole or a salt thereof can be produced by subjecting 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-lH-benzimidazole or a salt thereof to an optical resolution or subjecting 2-[1[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole to an asymmetrical oxidization to obtain the (R)-isomer, followed by crystallizing the resultant isomer.
Methods of optical resolution includes per se known methods,for example, a fractional recrystallization method, a chiral column method, a diastereomer method, and so forth.
Asymmetric oxidation includes per se known method.
The "fractional recrystallization method" includes a method in which a salt is formed between a racemate and an optically active compound [e.g., (+)-mandelic acid, (-)-mandelic acid, (+)-tartaric acid, (-)-tartaric acid, (+)-1-phenethylamine, (-)-1-phenethylamine, cinchonine, (-)-cinchonidine, brucine, etc.], which salt is separated by fractional recrystallization etc., and, if desired, subjected to a neutralization process, to give a free optical isomer.
The "chiral column method" includes a method in which a racemate or a salt thereof is applied to a column for optical isomer separation (chiral column). In the case'of liquid chromatography, for example, optical isomers are separated ~
by adding a racemate to a chiral column such as ENANTIO-OVM
(produced by Tosoh Corporation) or the DAICEL CHIRAL*series (produced by Daicel Corporation), and developing the racemate in water, a buffer (e.g., phosphate buffer), an organic solvent (e.g., hexane, ethanol, methanol, isopropanol, *Trade-mark acetonitrile, trifluoroacetic acid, diethylamine, triethylamine, etc.), or a solvent mixture thereof. In the case of gas chromatography, for example, a chiral column such as CP-Chirasil-DeX CB*(produced by GL Science) is used to separate optical isomers.
The "diastereomer method" includes a method in which a racemate and an optically active reagent are reacted (preferably, an optically active reagent is reacted to the 1-position of the benzimidazole group) to give a diastereomer mixture, which is then subjected to ordinary separation means (e.g., fractional recrystallization, chromatography, etc.) to obtain either diastereomer, which is subjected to a chemical reaction (e.g., acid hydrolysis, base hydrolysis, hydrogenolysis, etc.) to cut off the optically active reagent moiety, whereby the desired optical isomer is obtained. The "optically active reagent" includes, for example, an optically active organic acids such as MTPA [a-methoxy-a-(trifluoromethyl)phenylacetic acid] and (-)-menthoxyacetic acid; and an optically active alkoxymethyl halides such as (1R-endo)-2-(chloromethoxy)-1,3,3-trimethylbicyclo[2.2.1]heptane,-etc.
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof is produced by the methods described in JP-A-61-50978, USP 4,628,098 etc. or analogous methods thereto.
Methods of crystallization includes per se known methods, for example, a crystallization from solution, a crystallization from vapor, and a crystallization from molten form.
Methods of the "crystallization from solution" include, for example, a concentration method, a slow cooling method, a reaction method (diffusion method, electrolysis method), a hydrothermal growth method, a fusing agent method, and so forth. Solvents to be used include, for example, aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), *Trade-mark halogenated hydrocarbons(e.g., dichloromethane,chloroform, etc.), saturated hydrocarbons (e.g., hexane, heptane, cyclohexane, etc.), ethers (e.g., diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, etc.), nitriles (e.g., 5 acetonitrile, etc.), ketones (e.g., acetone, etc.), sulfoxides (e.g., dimethylsulfoxide, etc.), acid amides (e.g., N,N-dimethylformamide, etc.), esters (e.g., ethyl acetate, etc.), alcohols (e.g., methanol, ethanol, isopropyl alcohol, etc.), water, and so forth. These solvents may be used singly or in mixture of two or more kinds in appropriate ratios (e.g., 1:1 to 1:100).
Methods of the "crystallization from vapor" include, f or example, a gasification method (sealed tube method, gas stream method), a gas phase reaction method, a chemical transportation method, and so forth.
Methods of the "crystallization from molten form"
include, for example, a normal freezing method (pulling-up method, temperature gradient method, Bridgman method), a zone melting method (zone leveling method, float zone method), a special growth method (VLS method, liquid phase epitaxis method), and so forth.
For analyzing the crystal obtained, X-ray diffraction crystallographic analysis is commonly used. In addition, crystal orientation can also be determined by a mechanical method, an optical method, etc.
Thus obtained crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof (hereinafter also referred to as "crystal of the present invention") is useful as a pharmaceutical because it shows excellent antiulcer action, gastric acidsecretion -inhibiting action, mucosa-protecting action, anti-Helicobacter pylori action, etc., and because it is of low toxicity. Furthermore, by crystallizing the (R) -isomer, not only its stability is improved but also its handling is facilitated so that it can be prepared as a solid pharmaceutical composition with good reproducibility. In addition, when orally administered, the crystal of the present invention is more absorbable and more rapidly shows its action than the racemate. In addition, when administered, the crystal of the present invention shows a higher Cmax (maximum blood concentration) and a greater AUC (area under the concentration-time curve) than the racemate, and becomes more unlikely to be metabolized partly because of the increased protein-binding rate, thus showing an extended duration of action. The crystal of the present invention is therefore useful as a pharmaceutical of low doses and low prevalence of adverse reactions.
The crystal of the present invention is useful in mammals (e.g., humans, monkeys, sheep, bovines, horses, dogs, cats, rabbits, rats, mice, etc.) for the treatment and prevention of digestive ulcer (e.g., gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, etc.), gastritis, reflux esophagitis, NUD (non-ulcer dyspepsia), gastric cancer and gastric MALT lymphoma; Helicobacter pylori eradication; suppression of upper gastrointestinal hemorrhage due to digestive ulcer, acute stress ulcer and hemorrhagic gastritis; suppression of upper gastrointestinal hemorrhage due to invasive stress (stress from major surgery necessitating intensive management after surgery, and from cerebral vascular disorder, head trauma, multiple organ failure and extensive burn necessitating intensive treatment); treatment and prevention of ulcer caused by a nonsteroidal anti-inflammatory agent; treatment and prevention of hyperacidity and ulcer due to postoperative stress; pre-anesthetic administration etc.
The crystal of the present invention is of low toxicity and can be safely administered orally or non-orally (e.g., topical, rectal and intravenous administration, etc.), as such or in the form of pharmaceutical compositions formulated with a pharmacologically acceptable carrier, e.g., tablets (including sugar-coated tablets and film-coated tablets), powders, granules, capsules (including soft capsules), orally disintegrating tablets, liquids, injectable preparations, suppositories, sustained-release preparations and patches, in accordance with a commonly known method.
The content of the crystal of the present invention in the pharmaceutical composition of the present invention is about 0.01 to 100% by weight relative to the entire composition. Varying depending on subject of administration, route of administration, target disease etc., its dose is normally about 0. 5 to 1, 500 mg/day, preferably about 5 to 150 mg/day, based on the active ingredient, for example, when it is orally administered as an antiulcer agent to an adult human (60 kg). The crystal of the present invention may be administered once daily or in 2 to 3 divided portions per day.
Pharmacologically acceptable carriers that may be used to produce the pharmaceutical composition of the present invention include various organic or inorganic carrier substances in common use as pharmaceutical materials, including excipients, lubricants, binders, disintegrants, water-soluble polymers and basic inorganic salts for solid preparations; and solvents, dissolution aids, suspending agents, isotonizing agents, buffers and soothing agents for liquid preparations. Other ordinary pharmaceutical additives such as preservatives, antioxidants, coloring agents, sweetening agents, souring agents, bubbling agents and flavorings may also be used as necessary.
Such "excipients" include, for example, lactose, sucrose, D-mannitol, starch, cornstarch, crystalline cellulose, light silicic anhydride and titanium oxide.
Such "lubricants" include, for example, magnesium stearate, sucrose fatty acid esters, polyethylene glycol, talc and stearic acid.
Such "binders" include, for example, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, crystalline cellulose, a-starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan and low-substitutional hydroxypropyl cellulose.
Such "disintegrants" include (1) crosslinked povidone, (2) what is called super-disintegrants such as crosslinked carmellose sodium (FMC-Asahi Chemical) and carmellose calcium (6otoku Yakuhin), (3) carboxymethyl starch sodium (e.g., product of Matsutani Chemical), (4) low-substituted hydroxypropyl cellulose (e.g., product of Shin-Etsu Chemical), (5) cornstarch, and so forth. Said "crosslinked povidone" may be any crosslinked polymer having the chemical name 1-ethenyl-2-pyrrolidinone homopolymer, including polyvinylpyrrolidone (PVPP) and 1-vinyl-2-pyrrolidinone homopolyrner, and is exemplified by Colidon*CL (produced by BASF), Polyplasdon XL (produced by ISP), Polyplasdon XL-10 (produced by ISP) and Polyplasdon* INF-10 (produced by ISP).
Such "water-soluble polymers" include, for example, ethanol-soluble water-soluble polymers [e.g., cellulose derivatives such as hydroxypropyl cellulose (hereinafter also referred to as HPC), polyvinylpyrrolidone] and ethanol-insoluble water-soluble polymers [e.g., cellulose derivatives such as hydroxypropylmethyl cellulose (hereinafter also referred to as HPMC) , methyl cellulose and carboxymethyl cellulose sodium, sodium polyacrylate, polyvinyl alcohol, sodium alginate, guar gum].
Such "basic inorganic salts" include, for example,basic inorganic salts of sodium, potassium, magnesium and/or calcium. Preferred are basic inorganic salts of magnesium and/or calcium. More preferred are basic inorganic salts of magnesium. Such basic inorganic salts of sodium include, for example, sodium carbonate, sodium hydrogen carbonate, disodium hydrogenphosphate, etc. Such basic inorganic salts of potassium include, for example, potassium carbonate, potassium hydrogen carbonate, etc. Such basic inorganic *Trade-mark salts of magnesium include, for example, heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite [Mg6A12(OH)16-C03=4H20],alumina hydroxide magnesium, and so forth. Among others, pref erred is heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, etc. Such basic inorganic salts of calcium include, for example, precipitated calcium carbonate, calcium hydroxide, etc.
Such "solvents" include, for example, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and olive oil.
Such "dissolution aids" include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate and sodium citrate.
Such "suspending agents" include, for example, surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and monostearic glycerol;
and hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
Such " isotonizing agents" include, f or example, glucose, D-sorbitol, sodium chloride, glycerol and D-mannitol.
Such "buffers" include, for example, buffer solutions of phosphates, acetates, carbonates, citrates etc.
Such "soothing agents" include, for example, benzyl alcohol.
Such "preservatives" include, for example, p-oxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid.
Such "antioxidants" include, for example, sulfites, 26456-213(S) ascorbic acid and a-tocopherol.
Such "coloring agents" include, for example, food colors such as Food Color Yellow- No . 5, Food Color Red No. 2 and'Food Color Blue No. 2; and food lake colors and red oxide.
5 Such "sweetening agents" include, for example, saccharin sodium, dipotassium glycyrrhetinate, aspartame, stevia and thaumatin.
Such "souring agents" include,for example, citric acid (citric anhydride), tartaric acid and malic ackd.
The "salt" of "(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof" includes, for example, metal salts, salts with organic bases, salts with basic amino acids, and so forth. Preferred are physiologically acceptable salts.
Metal salts include, for example, alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt, magnesium salt and barium salt. Salts with organic bases include, for example, salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N-dibenzylethylenediamine, etc.
Salts with basic amino acids include, for example, salts with arginine, lysine, etc.
The crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof may be a hydrate or not.
Said "hydrate" includes 0.5 hydrate to 5.0 hydrate.
Among others, 0.5 hydrate, 1.0 hydrate, 1.5 hydrate, 2.0 hydrate and 2.5 hydrate are preferred. More preferred is 1.5 hydrate.
The crystal of .(R)=2-[[[3-methyl-4-(2,2,2-tri.fluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H=
benzimidazole or a salt thereof can be produced by subjecting 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-lH-benzimidazole or a salt thereof to an optical resolution or subjecting 2-[1[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole to an asymmetrical oxidization to obtain the (R)-isomer, followed by crystallizing the resultant isomer.
Methods of optical resolution includes per se known methods,for example, a fractional recrystallization method, a chiral column method, a diastereomer method, and so forth.
Asymmetric oxidation includes per se known method.
The "fractional recrystallization method" includes a method in which a salt is formed between a racemate and an optically active compound [e.g., (+)-mandelic acid, (-)-mandelic acid, (+)-tartaric acid, (-)-tartaric acid, (+)-1-phenethylamine, (-)-1-phenethylamine, cinchonine, (-)-cinchonidine, brucine, etc.], which salt is separated by fractional recrystallization etc., and, if desired, subjected to a neutralization process, to give a free optical isomer.
The "chiral column method" includes a method in which a racemate or a salt thereof is applied to a column for optical isomer separation (chiral column). In the case'of liquid chromatography, for example, optical isomers are separated ~
by adding a racemate to a chiral column such as ENANTIO-OVM
(produced by Tosoh Corporation) or the DAICEL CHIRAL*series (produced by Daicel Corporation), and developing the racemate in water, a buffer (e.g., phosphate buffer), an organic solvent (e.g., hexane, ethanol, methanol, isopropanol, *Trade-mark acetonitrile, trifluoroacetic acid, diethylamine, triethylamine, etc.), or a solvent mixture thereof. In the case of gas chromatography, for example, a chiral column such as CP-Chirasil-DeX CB*(produced by GL Science) is used to separate optical isomers.
The "diastereomer method" includes a method in which a racemate and an optically active reagent are reacted (preferably, an optically active reagent is reacted to the 1-position of the benzimidazole group) to give a diastereomer mixture, which is then subjected to ordinary separation means (e.g., fractional recrystallization, chromatography, etc.) to obtain either diastereomer, which is subjected to a chemical reaction (e.g., acid hydrolysis, base hydrolysis, hydrogenolysis, etc.) to cut off the optically active reagent moiety, whereby the desired optical isomer is obtained. The "optically active reagent" includes, for example, an optically active organic acids such as MTPA [a-methoxy-a-(trifluoromethyl)phenylacetic acid] and (-)-menthoxyacetic acid; and an optically active alkoxymethyl halides such as (1R-endo)-2-(chloromethoxy)-1,3,3-trimethylbicyclo[2.2.1]heptane,-etc.
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof is produced by the methods described in JP-A-61-50978, USP 4,628,098 etc. or analogous methods thereto.
Methods of crystallization includes per se known methods, for example, a crystallization from solution, a crystallization from vapor, and a crystallization from molten form.
Methods of the "crystallization from solution" include, for example, a concentration method, a slow cooling method, a reaction method (diffusion method, electrolysis method), a hydrothermal growth method, a fusing agent method, and so forth. Solvents to be used include, for example, aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), *Trade-mark halogenated hydrocarbons(e.g., dichloromethane,chloroform, etc.), saturated hydrocarbons (e.g., hexane, heptane, cyclohexane, etc.), ethers (e.g., diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, etc.), nitriles (e.g., 5 acetonitrile, etc.), ketones (e.g., acetone, etc.), sulfoxides (e.g., dimethylsulfoxide, etc.), acid amides (e.g., N,N-dimethylformamide, etc.), esters (e.g., ethyl acetate, etc.), alcohols (e.g., methanol, ethanol, isopropyl alcohol, etc.), water, and so forth. These solvents may be used singly or in mixture of two or more kinds in appropriate ratios (e.g., 1:1 to 1:100).
Methods of the "crystallization from vapor" include, f or example, a gasification method (sealed tube method, gas stream method), a gas phase reaction method, a chemical transportation method, and so forth.
Methods of the "crystallization from molten form"
include, for example, a normal freezing method (pulling-up method, temperature gradient method, Bridgman method), a zone melting method (zone leveling method, float zone method), a special growth method (VLS method, liquid phase epitaxis method), and so forth.
For analyzing the crystal obtained, X-ray diffraction crystallographic analysis is commonly used. In addition, crystal orientation can also be determined by a mechanical method, an optical method, etc.
Thus obtained crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof (hereinafter also referred to as "crystal of the present invention") is useful as a pharmaceutical because it shows excellent antiulcer action, gastric acidsecretion -inhibiting action, mucosa-protecting action, anti-Helicobacter pylori action, etc., and because it is of low toxicity. Furthermore, by crystallizing the (R) -isomer, not only its stability is improved but also its handling is facilitated so that it can be prepared as a solid pharmaceutical composition with good reproducibility. In addition, when orally administered, the crystal of the present invention is more absorbable and more rapidly shows its action than the racemate. In addition, when administered, the crystal of the present invention shows a higher Cmax (maximum blood concentration) and a greater AUC (area under the concentration-time curve) than the racemate, and becomes more unlikely to be metabolized partly because of the increased protein-binding rate, thus showing an extended duration of action. The crystal of the present invention is therefore useful as a pharmaceutical of low doses and low prevalence of adverse reactions.
The crystal of the present invention is useful in mammals (e.g., humans, monkeys, sheep, bovines, horses, dogs, cats, rabbits, rats, mice, etc.) for the treatment and prevention of digestive ulcer (e.g., gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, etc.), gastritis, reflux esophagitis, NUD (non-ulcer dyspepsia), gastric cancer and gastric MALT lymphoma; Helicobacter pylori eradication; suppression of upper gastrointestinal hemorrhage due to digestive ulcer, acute stress ulcer and hemorrhagic gastritis; suppression of upper gastrointestinal hemorrhage due to invasive stress (stress from major surgery necessitating intensive management after surgery, and from cerebral vascular disorder, head trauma, multiple organ failure and extensive burn necessitating intensive treatment); treatment and prevention of ulcer caused by a nonsteroidal anti-inflammatory agent; treatment and prevention of hyperacidity and ulcer due to postoperative stress; pre-anesthetic administration etc.
The crystal of the present invention is of low toxicity and can be safely administered orally or non-orally (e.g., topical, rectal and intravenous administration, etc.), as such or in the form of pharmaceutical compositions formulated with a pharmacologically acceptable carrier, e.g., tablets (including sugar-coated tablets and film-coated tablets), powders, granules, capsules (including soft capsules), orally disintegrating tablets, liquids, injectable preparations, suppositories, sustained-release preparations and patches, in accordance with a commonly known method.
The content of the crystal of the present invention in the pharmaceutical composition of the present invention is about 0.01 to 100% by weight relative to the entire composition. Varying depending on subject of administration, route of administration, target disease etc., its dose is normally about 0. 5 to 1, 500 mg/day, preferably about 5 to 150 mg/day, based on the active ingredient, for example, when it is orally administered as an antiulcer agent to an adult human (60 kg). The crystal of the present invention may be administered once daily or in 2 to 3 divided portions per day.
Pharmacologically acceptable carriers that may be used to produce the pharmaceutical composition of the present invention include various organic or inorganic carrier substances in common use as pharmaceutical materials, including excipients, lubricants, binders, disintegrants, water-soluble polymers and basic inorganic salts for solid preparations; and solvents, dissolution aids, suspending agents, isotonizing agents, buffers and soothing agents for liquid preparations. Other ordinary pharmaceutical additives such as preservatives, antioxidants, coloring agents, sweetening agents, souring agents, bubbling agents and flavorings may also be used as necessary.
Such "excipients" include, for example, lactose, sucrose, D-mannitol, starch, cornstarch, crystalline cellulose, light silicic anhydride and titanium oxide.
Such "lubricants" include, for example, magnesium stearate, sucrose fatty acid esters, polyethylene glycol, talc and stearic acid.
Such "binders" include, for example, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, crystalline cellulose, a-starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan and low-substitutional hydroxypropyl cellulose.
Such "disintegrants" include (1) crosslinked povidone, (2) what is called super-disintegrants such as crosslinked carmellose sodium (FMC-Asahi Chemical) and carmellose calcium (6otoku Yakuhin), (3) carboxymethyl starch sodium (e.g., product of Matsutani Chemical), (4) low-substituted hydroxypropyl cellulose (e.g., product of Shin-Etsu Chemical), (5) cornstarch, and so forth. Said "crosslinked povidone" may be any crosslinked polymer having the chemical name 1-ethenyl-2-pyrrolidinone homopolymer, including polyvinylpyrrolidone (PVPP) and 1-vinyl-2-pyrrolidinone homopolyrner, and is exemplified by Colidon*CL (produced by BASF), Polyplasdon XL (produced by ISP), Polyplasdon XL-10 (produced by ISP) and Polyplasdon* INF-10 (produced by ISP).
Such "water-soluble polymers" include, for example, ethanol-soluble water-soluble polymers [e.g., cellulose derivatives such as hydroxypropyl cellulose (hereinafter also referred to as HPC), polyvinylpyrrolidone] and ethanol-insoluble water-soluble polymers [e.g., cellulose derivatives such as hydroxypropylmethyl cellulose (hereinafter also referred to as HPMC) , methyl cellulose and carboxymethyl cellulose sodium, sodium polyacrylate, polyvinyl alcohol, sodium alginate, guar gum].
Such "basic inorganic salts" include, for example,basic inorganic salts of sodium, potassium, magnesium and/or calcium. Preferred are basic inorganic salts of magnesium and/or calcium. More preferred are basic inorganic salts of magnesium. Such basic inorganic salts of sodium include, for example, sodium carbonate, sodium hydrogen carbonate, disodium hydrogenphosphate, etc. Such basic inorganic salts of potassium include, for example, potassium carbonate, potassium hydrogen carbonate, etc. Such basic inorganic *Trade-mark salts of magnesium include, for example, heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicate, magnesium aluminate, synthetic hydrotalcite [Mg6A12(OH)16-C03=4H20],alumina hydroxide magnesium, and so forth. Among others, pref erred is heavy magnesium carbonate, magnesium carbonate, magnesium oxide, magnesium hydroxide, etc. Such basic inorganic salts of calcium include, for example, precipitated calcium carbonate, calcium hydroxide, etc.
Such "solvents" include, for example, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and olive oil.
Such "dissolution aids" include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate and sodium citrate.
Such "suspending agents" include, for example, surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and monostearic glycerol;
and hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
Such " isotonizing agents" include, f or example, glucose, D-sorbitol, sodium chloride, glycerol and D-mannitol.
Such "buffers" include, for example, buffer solutions of phosphates, acetates, carbonates, citrates etc.
Such "soothing agents" include, for example, benzyl alcohol.
Such "preservatives" include, for example, p-oxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid.
Such "antioxidants" include, for example, sulfites, 26456-213(S) ascorbic acid and a-tocopherol.
Such "coloring agents" include, for example, food colors such as Food Color Yellow- No . 5, Food Color Red No. 2 and'Food Color Blue No. 2; and food lake colors and red oxide.
5 Such "sweetening agents" include, for example, saccharin sodium, dipotassium glycyrrhetinate, aspartame, stevia and thaumatin.
Such "souring agents" include,for example, citric acid (citric anhydride), tartaric acid and malic ackd.
10 . Such "bubbling agents" include, for example, sodium bicarbonate.
Such "flavorings" may be synthetic substances or naturally occurring substances, and include, for example, lemon, lime, orange, menthol and strawberry.
The crystal of the present invent:iuii may be prepared as a preparation for oral administration in accordance with a commonly known method, by, for example, compression-shaping it in the presence of an excipient, a disintegrant, a binder, a lubricant, or the like, and subsequently coating it as necessary by a commonly known method for the purpose of taste masking, enteric dissolution or sustained release. For an enteric preparation, an intermediate layer may be provided by a commonly known method between the enteric layer and the drug-containing layer for the purpose of separation of the two layers.
For preparing the crystal of the present invention as an orally disintegrating tablet, available methods include, for example, a method in which a core containing crystalline cellulose and lactose is coated with the crystal of the present invention and a basic inorganic salt, and is further coated with a coating layer containing a water-soluble polymer, to give a composition, which is.coated with an enteric coating layer containing polyethylene glycol, further coated with an enteric coating layer containing triethyl citrate, still further coated with an enteric *Trade-mark 26456-213(S) ii coating layer containing polyethylene glycol, and still yet further coated with mannitol, to give fine granules, which are mixed with additives and shaped. The above-mentioned "enteric coating layer" includes, for example, aqueous enteric polymer substrates such as cellulose acetate phthalate (CAP), hydroxypropylmethyl cellulose phthalate, hydroxymethyl cellulose acetate succinate, methacrylic acid *
copolymers [e.g., Eudragit L30D-55 (trade name; produced by Rohm), Colicoat*MAE30DP (trade name; produced by BASF), Polykid*'PA30 (trade name; produced by San-yo Chemical)], carboxymethylethyl cellulose and shellac; sustained-release ~
substrates such as methacrylic acid polymers [e.g., Eudragit *
NE30D (trade name), Eudragit* RL30D (trade name), Eudragit RS30D (trade name), etc:]; wat'er-soluble polymers;
plasticizers such as triethyl citrate, polyethylene glycol, acetylated monoglycerides, triacetine and castor oil; and mixtures thereof. The above-mentioned "additive" includes, for example, water-soluble sugar alcohols (e.g., sorbitol, mannitol, multitol, reduced starch saccharides, xylitol, reduced paratinose,erythritol,etc.),crystalline cellulose [e.g., Ceolas ?x. KG 801, Avicel*PH 101, Avicel * PH 102, Avicel PH 301, Avicel PH 302, Avicel RC- 591 (crystalline cellulose =
carmellose sodium)], low-substituted hydroxypropyl cellulose [e.g., LH-22, LH-32, LH-23, LH-33 (Shin-Etsu Chemical) and mixtures thereof]; binders, souring agents, bubbling agents, sweetening agents, flavorings, lubricants, coloring agents,stabilizers,excipients,disintegrants etc.
are also used.
The crystal of the present invention may be used in combination with 1 to 3 other active ingredients.
Such "other active ingredients" include, for example, anti-Helicobacter pylori activity substances, imidazole compounds, bismuth salts, quinolone compounds, and so forth.
Of these substances, preferred are anti-Helicobacter pylori action substances, imidazole compounds etc. Such "anti-*Trade-mark Xelicobacter pylori action substances include, for example, antibiotic penicillins(e.g.,amoxicillin,benzylpenicillin, piperacillin, mecillinam, etc.), antibiotic cefems (e.g., cefixime, cefaclor, etc.), antibiotic macrolides (e.g., erythromycin, clarithromycin. etc.), antibiotic tetracyclines (e.g., tetracycline, minocycline, streptomycin, etc.), antibiotic aminoglycosides (e.g., gentamicin, amikacin, etc.), imipenem. and so forth. Of these substances, preferred are antibiotic penicillins, antibiotic macrolides etc. Such "imidazole compounds"
include, for example, metronidazole, miconazole, etc. Such "bismuth salts" include, for example, bismuth acetate, bismuth citrate, etc. Such "quinolone compounds" include, for example, ofloxacin, ciploxacin, etc.
Such "other active ingredients" and the crystal of the present invention may also be used in combination as, a mixture prepared as a single pharmaceutical composition [e.g.-, tablets, powders, granules, capsules (including soft capsules), liquids, injectable preparations, suppositories, sustained-release preparations, etc.], in accordance with a commonly known method, and rnay-also be prepared as separate preparations and administered to the same subject simultaneously or at a time interval.
BEST MODE FOR CARRYING OUT THE INVENTION
The present invention is hereinafter described in more detail by means of, but is not limited to, the following reference examples, examples and experimental examples.
In the following reference examples and examples, the term "room temperature" indicates about 15 to 30 C.
Melting points were measured using the Micro Melting Point Apparatus (produced by Yanagimoto Seisakusho), and uncorrected values are shown.
1H-NMR spectra were determined with CDC13 as the solvent using Varian Gemini-200*; data are shown in chemical shift *Trade-mark S(ppm) from the internal standard tetramethylsilane.
IR was determined using SHIMADZU FTIR-8200*
UV was determined using the HITACHI U-3200*
spectrophotometer.
Optical rotation [a]D was determined at 20 C using the DIP-370 digital polarimeter (produced by JASCO).
*
Optical purity was determined by HPLC (column: CHIRALCEL
OD 4. 6 mm dia. x 250 mm, temperature: about 20 C, mobile phase:
hexane/2-propanol = 80/20 or hexane/2-propanol = 85/15,flow rate: 1.0 ml/min, detection wavelength: 285nm)using a chiral column.
Crystal X-ray diffraction data for determining the absolute structure of sulf oxide were obtained by means of a 4-circle diffractometer (RIGAKU AFC5R) using the Cu-Kxa ray.
After the initial phase was determined by the direct method, the fine structure was' analyzed using SHELXL-93* X-ray powder diffraction was determined using the X-ray Powder Diffraction meter Rigaku RINT250e (ultraX18) No. PX-3.
The other symbols used herein have the following definitions:
s : singlet d : doublet t : triplet q : quartet m : multiplet bs: broad singlet J : binding constant Examples Reference Example 1 Isolation of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyll-lH-benzimidazole (R(+)-lansoprazole) 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole *Trade-mark (lansoprazole) (racemate) (3.98 g) was dissolved in the following mobile phase (330 ml) and acetonitrile (37 ml) and fractionated by HPLC (column: CHIRALCEL OD 20 mm dia. x 250 mm, temperature: 30 C, mobile phase: hexane/2-propanol/ethanol = 255/35/10, flow rate: 16ml/min, detection wavelength: 285 nm, 1 shot: 20-25 mg). Fractions of optical isomers of shorter retention time were combined and concentrated; the individual lots were combined and dissolved in ethanol and filtered through a 0.45 m filter; after hexane was added, the filtrate was again evaporated to dryness to yield R(+) -lansoprazole (1.6 g, optical purity > 97.6%ee) as an amorphous substance.
The amorphous substance obtained was subjected to fractionation and isolation in the same manner as above to yield R(+)-lansoprazole (1.37 g, optical purity > 99.9%ee) as an amorphous substance.
[a]D = + 174.3 (c = 0.994%, CHC13) Reference Example 2 Isolation of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) Lansoprazole (racemate) (34.2 g) was dissolved in 2-propanol (1,710 ml) and hexane (1,140 ml) containing triethylamine (0.2%) and fractionated by HPLC (column:
CHIRALCEL OD 50 mm dia. x 500 mm, temperature: room temperature, mobile phase: hexane/2-propanol = 85/15, flow rate: 60 ml/min, detection wavelength: 285 nm, 1 shot: about 300 mg) to isolate the individual optical isomers. Fractions of an optical isomer of shorter retention time were combined and concentrated; the individual lots were combined and dissolved in ethanol (250 ml); after triethylamine (3 ml) was added, the solution was filtered through a 0.45 m filter.
After the filtrate was concentrated, hexane was added, and the filtrate was again evaporated to dryness to yield R(+)-lansoprazole (9.31 g, optical purity 98.3%ee) as an amorphous substance.
Example 1 5 Crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) Amorphous R(+)-lansoprazole as obtained in Reference Example 1(100 mg ) was dissolved in acetonitrile (1 ml), which 10 was gradually evaporated at room temperature in a nitrogen stream. After a crystal began to form, diethyl ether (1.5 ml) was added and the container was stoppered and kept standing at room temperature.
The crystal thus formed was subjected to X-ray 15 structural analysis, and the absolute configuration of suifoxide was found to be the R-configuration by a method using a Flack parameter. The remaining portion of the crystal was collected by filtration, twice washed with diethyl ether (1 ml), and dried under reduced pressure, to yield crystals of R(+)-lansoprazole (38 mg).
m.p.: 144.0-144.5 C (dec.) Elemental analysis Calculated: C: 52.03, H: 3.82, N: 11.38, S: 8.68, F: 15.43, 0:8.66 Found: C: 52.08, H: 3.76, N: 11.58, S: 8.75, F: 15.42 1H-NMR: 2.25(3H,s), 4.40(2H,q,J=7.8Hz), 4.68(1H,d,J=13.8Hz), 4.85(1H,d,J=13.8Hz), 6.69(1H,d,J=6.OHz), 7.29-7.39(2H,m), 7.52(1H,m), 7.81(1H,m), 8.37(1H,d,J=6.OHz),11.00(1H,bs).
IR(1) cm-1): 3081, 3042, 2984, 1586, 1478, 1441, 1306, 1267, 1163.
UVmax(CHC13): 283.7 nm [a]D = + 199.2 (c = 0.202%, CHC13) Table 1 Crystal Data and Structure Refinement Parameters Molecular formula : C16H14N302F3S
Molecular weight : 369.36 Crystal color, habit : Colorless, tabular Crystal Dimension : 0.40 x 0.30 x 0.04 (mm) Crystal system : Monoclinic Lattice constants : a = 8.549(1) (A) b = 23.350(1) (A) c = 8.720(2) (A) (3 = 103.90(1) ( ) V = 1,689.8(4) (A) Space group P21 Z : 4 Density (calculated) : 1.452 (g/cm3) Effective reflection number/parameter number : 9.12 R (I z 2cf(I)) : 0.036 Flack parameter = -0.02(2) Example 2 Crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as obtained in Reference Example 2 (9.17 g) was dissolved in acetone (20 ml ), and water (15 ml) was added with gentle heating. After the solution was kept standing at room temperature overnight, water (20 ml) was added, followed by ultrasonication. After being collected by filtration, the solid was washed with water (30 ml, 20 ml), then washed with diisopropyl ether (20 ml), and dried under reduced pressure, to yield a solid ( 9. 10 g). The solid obtained (9. 00 g) was dissolved in acetone (30 ml), and after the solution was filtered, diisopropyl ether (50 ml) was added to the filtrate.
A crystal seed was placed, and the mixture was kept standing at room temperature overnight. Precipitated crystals were collected by filtration, washed 3 times with diisopropyl ether (10 ml), and dried under reduced pressure, to yield crystals (7.85 g). The crystals obtained (7.80 g) were dissolved under heating in acetone (22.5 ml) and water (30 ml) , and this solution was kept standing at room temperature for1hour. A precipitated solid was collected by filtration, washed with acetone-water (1:4) (15 ml), and dried under reduced pressure, to yield a solid (3.88 g). The solid obtained (3.88 g) was dissolved under heating in acetone (4 ml) and diisopropyl ether (14 ml) was added. This solution was kept standing at room temperature for 30 minutes.
Precipitated crystals were collected by filtration, twice washed with diisopropyl ether (6 ml), and dried under reduced pressure, to yield crystals of R(+)-lansoprazole (3.40 g, optical purity 99.8%ee).
m.p.: 147.0-148.0 C (dec.) Elemental analysis Calculated: C: 52.03, H: 3.82, N: 11.38, S: 8.68, F: 15.43, 0: 8.66 Found: C: 51.85, H: 3.92, N: 11.26, S: 8.82, F: 15.22 1H-NMR: 2.24(3H,s), 4.38(2H,q,J=7.8Hz), 4.74(1H,d,J=13.6Hz), 4.87(1H,d,J=13.6Hz), 6.68(1H,d,J=5.8Hz), 7.26-7.36(2H,m), 7.45(1H,m), 7.78(1H,m), 8.35(1H,d,J=5.8Hz).
IR( v cm-1) : 3083, 3034, 2975, 1586, 1478, 1441, 1306, 1267, UVmax(CHC13): 283.6 nm [a]D = + 180.3 (c = 1.004%, CHC13) Table 2 X-ray Powder Diffraction Data 20 ( ) Half-value d-value (A) Relative width intensity (%) 7.560 0.141 11.6841 100 13.060 0.165 6.7733 44 15.160 0.141 5.8394 55 15.440 0.141 5.7342 84 20.040 0.165 4.4271 23 21.720 0.165 4.0883 89 22.560 0.141 3.9380 24 22.820 0.141 3.8937 24 24.080 0.165 3.6927 37 26.120 0.118 3.4088 32 28.680 0.165 3.1100 20 Example 3 Crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) 1.5 hydrate Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as obtained in Reference Example 1 (100 mg) was dissolved in ethanol (0. 15 ml ), and water ( 0.15 ml) was added.
After a seed was placed, the solution was kept standing at room temperature for 1 hour. Precipitated crystals were collected by filtration, twice. washed with water (2 ml ), and dried under reduced pressure, to yield crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) 1.5 hydrate (96 mg).
m.p.: 76.0-80.0 C
Elemental analysis Calculated: C: 48.48, H: 4.32, N: 10.60, S: 8.09, F: 14.38, 0: 14.13 Found: C: 48.52, H: 4.44, N: 10.49 Table 3 X-ray Powder Diffraction Data 20 ( ) Half-value d-value (A) Relative width intensity (%) 6.680 0.165 13.2212 9 9.200 0.165 9.6046 21 9.960 0.141 8.8734 25 10.980 0.165 8.0513 42 13.380 0.141 6.6120 22 14.960 0.141 5.9170 63 15.680 0.165 5.6469 100 17.640 0.212 5.0237 34 19.760 0.212 4.4892 33 25.420 0.188 3.5010 23 29.800 0.188 2.9957 20 Experimental Example 1 Suppressive action on gastric mucosal injury due to stress of water immersion restraint in rat Male SD rats (7 weeks of age, weighing 230 to 250 g) were fasted for 24 hours, after which they were stressed by being housed in restraint cages and immersed to below the xiphoid process in a standing position in a 23 C constant-temperature water chamber. Af ter 5 hours, the rats were removed from the cages and sacrificed using gaseous carbon dioxide, and their stomachs excised. After the lower portion of the esophagus was clipped, a 1% formalin solution (10 ml) was injected into the stomach via the duodenum, which was then occluded, and the stomach was immersed in the same solution. After 10 minutes, an incision was made along the greater curvature, and the length (mm) of each mucosal injury was measured under a stereomicroscope. The overall sum of the injury lengths in each stomach was taken as the.gastric mucosal injury index.
The crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) as obtained in Example 2 were suspended in 0.5% methyl cellulose (pH 9.5) containing 5 0.05 M NaHCO3 and orally administered at 30 minutes before stressing (dosing volume 2 ml/kg). Each treatment group comprised 9 animals. The control group (solvent administration group) and the drug administration group were compared by Steel's test.
10 The results are shown in Table 4.
Table 4 Sample Dose Gastric mucosal Suppression (mg/kg) injury index (mm) rate (~) Control - 10.9 t 1.9 -(R)-lansoprazole 3 0.2 t 0.2* 98.0 crystal Each figure of gastric mucosal injury index is the mean t 15 standard error for the 9 animals in each group.
*p < 0.01 (versus control group, Steel's test) Experimental Example 2 The crystals of R(+) -lansoprazole as obtained in Example 20 2 (about 5 mg) and amorphous R(+)-lansoprazole as obtained in Reference Example 1 (about 5 mg) were each taken in a colorless glass bottle, and their stability during storage at 60 C (stopper removed) was examined. A 25 ml solution (concentration: about 0.2 mg/ml) of the sample after completion of storage in the mobile phase, along with a standard solution prepared using the initial lot, was analyzed under the HPLC conditions shown below, and the R(+)-lansoprazole content (residual percentage) was calculated from the peak area obtained. The results are shown in Table 5.
HPLC analytical conditions Detection wavelength : UV 275 nm Column : YMC Pro C18, 4.6 x 150 mm Mobile phase : Fluid prepared by adding phosphoric acid to water/acetonitrile/triethyl amine ( 63 : 37 : 1) to reach pH 7.
Flow rate : 1.0 ml/min Column temperature : 40 C
Sample injection volume : 10 .l Table 5 Stability of R(+)-Lansoprazole Crystal and Amorphous Sample Duration of Description Content (Residual storage percentage) Crystal 1 week Light-brown 97.0 2 weeks Brown 93.8 4 weeks Brown 91.7 Amorphous 1 week Brown 70.8 2 weeks Blackish brown 57.5 When the sample was stored at 60 C (exposed), the crystal of Example 2 retained a content exceeding 90% for up to 4 weeks, whereas the amorphous form of Reference Example 1 showed reduction in content to 70.8% after 1 week and 57.5%
after 2 weeks. This finding demonstrates that the crystal of R(+)-lansoprazole is more stable and more preferable for use as a pharmaceutical etc. than the amorphous form.
INDUSTRIAL APPLICABILITY
The crystal of the present invention is useful as a pharmaceutical because it shows excellent antiulcer action, gastric acid secretion-inhibit action, mucosa-protecting action, anti-Helicobacter pylori action etc., and because it is of low toxicity. Furthermore, by crystallizing the (R)-isomer, not only its stability is improved but also its handling is facilitated so that it can be prepared as a solid pharmaceutical composition with good reproducibility. In addition, when orally administered, the crystal of the present invention is more absorbable and more rapidly shows its action than the racemate. In addition, when administered, the crystal of the present invention shows a higher Cmax and a greater AUC than the racemate, and becomes more unlikely to be metabolized partly because of the increased protein-binding rate, thus showing an extended duration of action. The crystal of the present invention is therefore useful as a pharmaceutical of low doses and low prevalence of adverse reactions.
Such "flavorings" may be synthetic substances or naturally occurring substances, and include, for example, lemon, lime, orange, menthol and strawberry.
The crystal of the present invent:iuii may be prepared as a preparation for oral administration in accordance with a commonly known method, by, for example, compression-shaping it in the presence of an excipient, a disintegrant, a binder, a lubricant, or the like, and subsequently coating it as necessary by a commonly known method for the purpose of taste masking, enteric dissolution or sustained release. For an enteric preparation, an intermediate layer may be provided by a commonly known method between the enteric layer and the drug-containing layer for the purpose of separation of the two layers.
For preparing the crystal of the present invention as an orally disintegrating tablet, available methods include, for example, a method in which a core containing crystalline cellulose and lactose is coated with the crystal of the present invention and a basic inorganic salt, and is further coated with a coating layer containing a water-soluble polymer, to give a composition, which is.coated with an enteric coating layer containing polyethylene glycol, further coated with an enteric coating layer containing triethyl citrate, still further coated with an enteric *Trade-mark 26456-213(S) ii coating layer containing polyethylene glycol, and still yet further coated with mannitol, to give fine granules, which are mixed with additives and shaped. The above-mentioned "enteric coating layer" includes, for example, aqueous enteric polymer substrates such as cellulose acetate phthalate (CAP), hydroxypropylmethyl cellulose phthalate, hydroxymethyl cellulose acetate succinate, methacrylic acid *
copolymers [e.g., Eudragit L30D-55 (trade name; produced by Rohm), Colicoat*MAE30DP (trade name; produced by BASF), Polykid*'PA30 (trade name; produced by San-yo Chemical)], carboxymethylethyl cellulose and shellac; sustained-release ~
substrates such as methacrylic acid polymers [e.g., Eudragit *
NE30D (trade name), Eudragit* RL30D (trade name), Eudragit RS30D (trade name), etc:]; wat'er-soluble polymers;
plasticizers such as triethyl citrate, polyethylene glycol, acetylated monoglycerides, triacetine and castor oil; and mixtures thereof. The above-mentioned "additive" includes, for example, water-soluble sugar alcohols (e.g., sorbitol, mannitol, multitol, reduced starch saccharides, xylitol, reduced paratinose,erythritol,etc.),crystalline cellulose [e.g., Ceolas ?x. KG 801, Avicel*PH 101, Avicel * PH 102, Avicel PH 301, Avicel PH 302, Avicel RC- 591 (crystalline cellulose =
carmellose sodium)], low-substituted hydroxypropyl cellulose [e.g., LH-22, LH-32, LH-23, LH-33 (Shin-Etsu Chemical) and mixtures thereof]; binders, souring agents, bubbling agents, sweetening agents, flavorings, lubricants, coloring agents,stabilizers,excipients,disintegrants etc.
are also used.
The crystal of the present invention may be used in combination with 1 to 3 other active ingredients.
Such "other active ingredients" include, for example, anti-Helicobacter pylori activity substances, imidazole compounds, bismuth salts, quinolone compounds, and so forth.
Of these substances, preferred are anti-Helicobacter pylori action substances, imidazole compounds etc. Such "anti-*Trade-mark Xelicobacter pylori action substances include, for example, antibiotic penicillins(e.g.,amoxicillin,benzylpenicillin, piperacillin, mecillinam, etc.), antibiotic cefems (e.g., cefixime, cefaclor, etc.), antibiotic macrolides (e.g., erythromycin, clarithromycin. etc.), antibiotic tetracyclines (e.g., tetracycline, minocycline, streptomycin, etc.), antibiotic aminoglycosides (e.g., gentamicin, amikacin, etc.), imipenem. and so forth. Of these substances, preferred are antibiotic penicillins, antibiotic macrolides etc. Such "imidazole compounds"
include, for example, metronidazole, miconazole, etc. Such "bismuth salts" include, for example, bismuth acetate, bismuth citrate, etc. Such "quinolone compounds" include, for example, ofloxacin, ciploxacin, etc.
Such "other active ingredients" and the crystal of the present invention may also be used in combination as, a mixture prepared as a single pharmaceutical composition [e.g.-, tablets, powders, granules, capsules (including soft capsules), liquids, injectable preparations, suppositories, sustained-release preparations, etc.], in accordance with a commonly known method, and rnay-also be prepared as separate preparations and administered to the same subject simultaneously or at a time interval.
BEST MODE FOR CARRYING OUT THE INVENTION
The present invention is hereinafter described in more detail by means of, but is not limited to, the following reference examples, examples and experimental examples.
In the following reference examples and examples, the term "room temperature" indicates about 15 to 30 C.
Melting points were measured using the Micro Melting Point Apparatus (produced by Yanagimoto Seisakusho), and uncorrected values are shown.
1H-NMR spectra were determined with CDC13 as the solvent using Varian Gemini-200*; data are shown in chemical shift *Trade-mark S(ppm) from the internal standard tetramethylsilane.
IR was determined using SHIMADZU FTIR-8200*
UV was determined using the HITACHI U-3200*
spectrophotometer.
Optical rotation [a]D was determined at 20 C using the DIP-370 digital polarimeter (produced by JASCO).
*
Optical purity was determined by HPLC (column: CHIRALCEL
OD 4. 6 mm dia. x 250 mm, temperature: about 20 C, mobile phase:
hexane/2-propanol = 80/20 or hexane/2-propanol = 85/15,flow rate: 1.0 ml/min, detection wavelength: 285nm)using a chiral column.
Crystal X-ray diffraction data for determining the absolute structure of sulf oxide were obtained by means of a 4-circle diffractometer (RIGAKU AFC5R) using the Cu-Kxa ray.
After the initial phase was determined by the direct method, the fine structure was' analyzed using SHELXL-93* X-ray powder diffraction was determined using the X-ray Powder Diffraction meter Rigaku RINT250e (ultraX18) No. PX-3.
The other symbols used herein have the following definitions:
s : singlet d : doublet t : triplet q : quartet m : multiplet bs: broad singlet J : binding constant Examples Reference Example 1 Isolation of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyll-lH-benzimidazole (R(+)-lansoprazole) 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole *Trade-mark (lansoprazole) (racemate) (3.98 g) was dissolved in the following mobile phase (330 ml) and acetonitrile (37 ml) and fractionated by HPLC (column: CHIRALCEL OD 20 mm dia. x 250 mm, temperature: 30 C, mobile phase: hexane/2-propanol/ethanol = 255/35/10, flow rate: 16ml/min, detection wavelength: 285 nm, 1 shot: 20-25 mg). Fractions of optical isomers of shorter retention time were combined and concentrated; the individual lots were combined and dissolved in ethanol and filtered through a 0.45 m filter; after hexane was added, the filtrate was again evaporated to dryness to yield R(+) -lansoprazole (1.6 g, optical purity > 97.6%ee) as an amorphous substance.
The amorphous substance obtained was subjected to fractionation and isolation in the same manner as above to yield R(+)-lansoprazole (1.37 g, optical purity > 99.9%ee) as an amorphous substance.
[a]D = + 174.3 (c = 0.994%, CHC13) Reference Example 2 Isolation of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) Lansoprazole (racemate) (34.2 g) was dissolved in 2-propanol (1,710 ml) and hexane (1,140 ml) containing triethylamine (0.2%) and fractionated by HPLC (column:
CHIRALCEL OD 50 mm dia. x 500 mm, temperature: room temperature, mobile phase: hexane/2-propanol = 85/15, flow rate: 60 ml/min, detection wavelength: 285 nm, 1 shot: about 300 mg) to isolate the individual optical isomers. Fractions of an optical isomer of shorter retention time were combined and concentrated; the individual lots were combined and dissolved in ethanol (250 ml); after triethylamine (3 ml) was added, the solution was filtered through a 0.45 m filter.
After the filtrate was concentrated, hexane was added, and the filtrate was again evaporated to dryness to yield R(+)-lansoprazole (9.31 g, optical purity 98.3%ee) as an amorphous substance.
Example 1 5 Crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) Amorphous R(+)-lansoprazole as obtained in Reference Example 1(100 mg ) was dissolved in acetonitrile (1 ml), which 10 was gradually evaporated at room temperature in a nitrogen stream. After a crystal began to form, diethyl ether (1.5 ml) was added and the container was stoppered and kept standing at room temperature.
The crystal thus formed was subjected to X-ray 15 structural analysis, and the absolute configuration of suifoxide was found to be the R-configuration by a method using a Flack parameter. The remaining portion of the crystal was collected by filtration, twice washed with diethyl ether (1 ml), and dried under reduced pressure, to yield crystals of R(+)-lansoprazole (38 mg).
m.p.: 144.0-144.5 C (dec.) Elemental analysis Calculated: C: 52.03, H: 3.82, N: 11.38, S: 8.68, F: 15.43, 0:8.66 Found: C: 52.08, H: 3.76, N: 11.58, S: 8.75, F: 15.42 1H-NMR: 2.25(3H,s), 4.40(2H,q,J=7.8Hz), 4.68(1H,d,J=13.8Hz), 4.85(1H,d,J=13.8Hz), 6.69(1H,d,J=6.OHz), 7.29-7.39(2H,m), 7.52(1H,m), 7.81(1H,m), 8.37(1H,d,J=6.OHz),11.00(1H,bs).
IR(1) cm-1): 3081, 3042, 2984, 1586, 1478, 1441, 1306, 1267, 1163.
UVmax(CHC13): 283.7 nm [a]D = + 199.2 (c = 0.202%, CHC13) Table 1 Crystal Data and Structure Refinement Parameters Molecular formula : C16H14N302F3S
Molecular weight : 369.36 Crystal color, habit : Colorless, tabular Crystal Dimension : 0.40 x 0.30 x 0.04 (mm) Crystal system : Monoclinic Lattice constants : a = 8.549(1) (A) b = 23.350(1) (A) c = 8.720(2) (A) (3 = 103.90(1) ( ) V = 1,689.8(4) (A) Space group P21 Z : 4 Density (calculated) : 1.452 (g/cm3) Effective reflection number/parameter number : 9.12 R (I z 2cf(I)) : 0.036 Flack parameter = -0.02(2) Example 2 Crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as obtained in Reference Example 2 (9.17 g) was dissolved in acetone (20 ml ), and water (15 ml) was added with gentle heating. After the solution was kept standing at room temperature overnight, water (20 ml) was added, followed by ultrasonication. After being collected by filtration, the solid was washed with water (30 ml, 20 ml), then washed with diisopropyl ether (20 ml), and dried under reduced pressure, to yield a solid ( 9. 10 g). The solid obtained (9. 00 g) was dissolved in acetone (30 ml), and after the solution was filtered, diisopropyl ether (50 ml) was added to the filtrate.
A crystal seed was placed, and the mixture was kept standing at room temperature overnight. Precipitated crystals were collected by filtration, washed 3 times with diisopropyl ether (10 ml), and dried under reduced pressure, to yield crystals (7.85 g). The crystals obtained (7.80 g) were dissolved under heating in acetone (22.5 ml) and water (30 ml) , and this solution was kept standing at room temperature for1hour. A precipitated solid was collected by filtration, washed with acetone-water (1:4) (15 ml), and dried under reduced pressure, to yield a solid (3.88 g). The solid obtained (3.88 g) was dissolved under heating in acetone (4 ml) and diisopropyl ether (14 ml) was added. This solution was kept standing at room temperature for 30 minutes.
Precipitated crystals were collected by filtration, twice washed with diisopropyl ether (6 ml), and dried under reduced pressure, to yield crystals of R(+)-lansoprazole (3.40 g, optical purity 99.8%ee).
m.p.: 147.0-148.0 C (dec.) Elemental analysis Calculated: C: 52.03, H: 3.82, N: 11.38, S: 8.68, F: 15.43, 0: 8.66 Found: C: 51.85, H: 3.92, N: 11.26, S: 8.82, F: 15.22 1H-NMR: 2.24(3H,s), 4.38(2H,q,J=7.8Hz), 4.74(1H,d,J=13.6Hz), 4.87(1H,d,J=13.6Hz), 6.68(1H,d,J=5.8Hz), 7.26-7.36(2H,m), 7.45(1H,m), 7.78(1H,m), 8.35(1H,d,J=5.8Hz).
IR( v cm-1) : 3083, 3034, 2975, 1586, 1478, 1441, 1306, 1267, UVmax(CHC13): 283.6 nm [a]D = + 180.3 (c = 1.004%, CHC13) Table 2 X-ray Powder Diffraction Data 20 ( ) Half-value d-value (A) Relative width intensity (%) 7.560 0.141 11.6841 100 13.060 0.165 6.7733 44 15.160 0.141 5.8394 55 15.440 0.141 5.7342 84 20.040 0.165 4.4271 23 21.720 0.165 4.0883 89 22.560 0.141 3.9380 24 22.820 0.141 3.8937 24 24.080 0.165 3.6927 37 26.120 0.118 3.4088 32 28.680 0.165 3.1100 20 Example 3 Crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) 1.5 hydrate Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as obtained in Reference Example 1 (100 mg) was dissolved in ethanol (0. 15 ml ), and water ( 0.15 ml) was added.
After a seed was placed, the solution was kept standing at room temperature for 1 hour. Precipitated crystals were collected by filtration, twice. washed with water (2 ml ), and dried under reduced pressure, to yield crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) 1.5 hydrate (96 mg).
m.p.: 76.0-80.0 C
Elemental analysis Calculated: C: 48.48, H: 4.32, N: 10.60, S: 8.09, F: 14.38, 0: 14.13 Found: C: 48.52, H: 4.44, N: 10.49 Table 3 X-ray Powder Diffraction Data 20 ( ) Half-value d-value (A) Relative width intensity (%) 6.680 0.165 13.2212 9 9.200 0.165 9.6046 21 9.960 0.141 8.8734 25 10.980 0.165 8.0513 42 13.380 0.141 6.6120 22 14.960 0.141 5.9170 63 15.680 0.165 5.6469 100 17.640 0.212 5.0237 34 19.760 0.212 4.4892 33 25.420 0.188 3.5010 23 29.800 0.188 2.9957 20 Experimental Example 1 Suppressive action on gastric mucosal injury due to stress of water immersion restraint in rat Male SD rats (7 weeks of age, weighing 230 to 250 g) were fasted for 24 hours, after which they were stressed by being housed in restraint cages and immersed to below the xiphoid process in a standing position in a 23 C constant-temperature water chamber. Af ter 5 hours, the rats were removed from the cages and sacrificed using gaseous carbon dioxide, and their stomachs excised. After the lower portion of the esophagus was clipped, a 1% formalin solution (10 ml) was injected into the stomach via the duodenum, which was then occluded, and the stomach was immersed in the same solution. After 10 minutes, an incision was made along the greater curvature, and the length (mm) of each mucosal injury was measured under a stereomicroscope. The overall sum of the injury lengths in each stomach was taken as the.gastric mucosal injury index.
The crystals of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (R(+)-lansoprazole) as obtained in Example 2 were suspended in 0.5% methyl cellulose (pH 9.5) containing 5 0.05 M NaHCO3 and orally administered at 30 minutes before stressing (dosing volume 2 ml/kg). Each treatment group comprised 9 animals. The control group (solvent administration group) and the drug administration group were compared by Steel's test.
10 The results are shown in Table 4.
Table 4 Sample Dose Gastric mucosal Suppression (mg/kg) injury index (mm) rate (~) Control - 10.9 t 1.9 -(R)-lansoprazole 3 0.2 t 0.2* 98.0 crystal Each figure of gastric mucosal injury index is the mean t 15 standard error for the 9 animals in each group.
*p < 0.01 (versus control group, Steel's test) Experimental Example 2 The crystals of R(+) -lansoprazole as obtained in Example 20 2 (about 5 mg) and amorphous R(+)-lansoprazole as obtained in Reference Example 1 (about 5 mg) were each taken in a colorless glass bottle, and their stability during storage at 60 C (stopper removed) was examined. A 25 ml solution (concentration: about 0.2 mg/ml) of the sample after completion of storage in the mobile phase, along with a standard solution prepared using the initial lot, was analyzed under the HPLC conditions shown below, and the R(+)-lansoprazole content (residual percentage) was calculated from the peak area obtained. The results are shown in Table 5.
HPLC analytical conditions Detection wavelength : UV 275 nm Column : YMC Pro C18, 4.6 x 150 mm Mobile phase : Fluid prepared by adding phosphoric acid to water/acetonitrile/triethyl amine ( 63 : 37 : 1) to reach pH 7.
Flow rate : 1.0 ml/min Column temperature : 40 C
Sample injection volume : 10 .l Table 5 Stability of R(+)-Lansoprazole Crystal and Amorphous Sample Duration of Description Content (Residual storage percentage) Crystal 1 week Light-brown 97.0 2 weeks Brown 93.8 4 weeks Brown 91.7 Amorphous 1 week Brown 70.8 2 weeks Blackish brown 57.5 When the sample was stored at 60 C (exposed), the crystal of Example 2 retained a content exceeding 90% for up to 4 weeks, whereas the amorphous form of Reference Example 1 showed reduction in content to 70.8% after 1 week and 57.5%
after 2 weeks. This finding demonstrates that the crystal of R(+)-lansoprazole is more stable and more preferable for use as a pharmaceutical etc. than the amorphous form.
INDUSTRIAL APPLICABILITY
The crystal of the present invention is useful as a pharmaceutical because it shows excellent antiulcer action, gastric acid secretion-inhibit action, mucosa-protecting action, anti-Helicobacter pylori action etc., and because it is of low toxicity. Furthermore, by crystallizing the (R)-isomer, not only its stability is improved but also its handling is facilitated so that it can be prepared as a solid pharmaceutical composition with good reproducibility. In addition, when orally administered, the crystal of the present invention is more absorbable and more rapidly shows its action than the racemate. In addition, when administered, the crystal of the present invention shows a higher Cmax and a greater AUC than the racemate, and becomes more unlikely to be metabolized partly because of the increased protein-binding rate, thus showing an extended duration of action. The crystal of the present invention is therefore useful as a pharmaceutical of low doses and low prevalence of adverse reactions.
Claims (11)
1. A crystal of:
(i) the compound(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, (ii) a physiologically acceptable salt thereof, or (iii) a hydrate of the compound or salt.
(i) the compound(R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, (ii) a physiologically acceptable salt thereof, or (iii) a hydrate of the compound or salt.
2. A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.
3. The crystal according to claim 2, which exhibits an X-ray powder diffraction analysis pattern having characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.
4. The crystal according to any one of claims 1 to 3, wherein the compound has an optical purity of at least 99.8%ee.
5. A pharmaceutical composition which comprises:
the crystal as defined in any one of claims 1 to 4, and a pharmacologically acceptable carrier.
the crystal as defined in any one of claims 1 to 4, and a pharmacologically acceptable carrier.
6. The pharmaceutical composition according to claim 5, which is for treating or preventing digestive ulcer.
7. The pharmaceutical composition according to claim 5, which is for treating or preventing reflux esophagitis.
8. Use of the crystal as defined in any one of claims 1 to 4, for manufacturing a pharmaceutical composition for treating or preventing digestive ulcer.
9. Use of the crystal as defined in any one of claims 1 to 4, for manufacturing a pharmaceutical composition for treating or preventing reflux esophagitis.
10. A method for producing a crystal of the compound (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a hydrate of the compound, which comprises:
subjecting 2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole racemate to an optical resolution to obtain (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as an amorphous substance;
dissolving the amorphous substance in a solvent to obtain a solution of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole dissolved in the solvent;
concentrating the solution or adding water to the solution so as to crystallize (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; and collecting the crystal of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole from the solution, wherein:
(i) the solvent is acetonitrile; and the solvent is gradually evaporated at room temperature for the crystallization, whereby the crystal of the compound is produced;
(ii) the solvent is acetone; and water is added to the solution for the crystallization, whereby the crystal of the compound is produced; or (iii) the solvent is ethanol; and water is added to the solution for the crystallization, whereby the crystal of the hydrate of the compound is produced.
subjecting 2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole racemate to an optical resolution to obtain (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as an amorphous substance;
dissolving the amorphous substance in a solvent to obtain a solution of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole dissolved in the solvent;
concentrating the solution or adding water to the solution so as to crystallize (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; and collecting the crystal of (R)-2-[[[3-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole from the solution, wherein:
(i) the solvent is acetonitrile; and the solvent is gradually evaporated at room temperature for the crystallization, whereby the crystal of the compound is produced;
(ii) the solvent is acetone; and water is added to the solution for the crystallization, whereby the crystal of the compound is produced; or (iii) the solvent is ethanol; and water is added to the solution for the crystallization, whereby the crystal of the hydrate of the compound is produced.
11. The method according to claim 10, wherein the optical resolution is carried out by using a chiral column.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17150999 | 1999-06-17 | ||
| JP11/171509 | 1999-06-17 | ||
| PCT/JP2000/003880 WO2000078745A2 (en) | 1999-06-17 | 2000-06-15 | Crystalline form of (r)-2-[[[3-methyl- 4- (2,2,2,- trifluoroethoxy) -2- pyridinyl] methyl] sulfinyl] -1h-benzimidazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2375201A1 CA2375201A1 (en) | 2000-12-28 |
| CA2375201C true CA2375201C (en) | 2010-02-09 |
Family
ID=15924444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2375201A Expired - Lifetime CA2375201C (en) | 1999-06-17 | 2000-06-15 | Crystal of (r)-lansoprazole |
Country Status (27)
| Country | Link |
|---|---|
| US (11) | US6462058B1 (en) |
| EP (3) | EP2343289A1 (en) |
| KR (3) | KR100537029B1 (en) |
| CN (1) | CN1150186C (en) |
| AR (5) | AR031069A1 (en) |
| AT (1) | ATE391126T1 (en) |
| AU (1) | AU778820B2 (en) |
| BE (1) | BE2014C017I2 (en) |
| BR (1) | BRPI0011674B8 (en) |
| CA (1) | CA2375201C (en) |
| CY (2) | CY1110384T1 (en) |
| DE (1) | DE60038481T2 (en) |
| DK (2) | DK1129088T3 (en) |
| ES (2) | ES2300265T3 (en) |
| HK (2) | HK1038227A1 (en) |
| HU (1) | HU229067B1 (en) |
| IL (2) | IL145996A0 (en) |
| MX (1) | MXPA01012642A (en) |
| MY (1) | MY125399A (en) |
| NO (1) | NO321168B1 (en) |
| NZ (1) | NZ515702A (en) |
| PL (1) | PL201068B1 (en) |
| PT (2) | PT1129088E (en) |
| SI (1) | SI1129088T1 (en) |
| TW (2) | TWI275587B (en) |
| WO (2) | WO2004083200A1 (en) |
| ZA (1) | ZA200108331B (en) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US20040224989A1 (en) * | 1999-01-29 | 2004-11-11 | Barberich Timothy J. | S-lansoprazole compositions and methods |
| TWI275587B (en) * | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| PT1191025E (en) * | 1999-06-30 | 2005-09-30 | Takeda Pharmaceutical | LANSOPRAZOL CRYSTALS |
| AU2001252595A1 (en) | 2000-04-28 | 2001-11-12 | Takeda Chemical Industries Ltd. | Process for producing optically active sulfoxide derivative |
| ES2511774T3 (en) | 2000-05-15 | 2014-10-23 | Takeda Pharmaceutical Company Limited | Crystal forms of (R) -lansoprazole |
| WO2002012225A1 (en) * | 2000-08-04 | 2002-02-14 | Takeda Chemical Industries, Ltd. | Salts of benzimidazole compound and use thereof |
| DK1337525T3 (en) * | 2000-12-01 | 2011-09-19 | Takeda Pharmaceutical | Process for crystallizing (R) - or (S) -lansoprazole |
| WO2003032953A1 (en) | 2001-10-17 | 2003-04-24 | Takeda Chemical Industries, Ltd. | Granules containing acid-unstable chemical in large amount |
| KR100467100B1 (en) * | 2002-03-20 | 2005-01-24 | 일양약품주식회사 | A process for preparation of injection containing 2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl-5-(1H-pyrrol-1-yl)-1H-benzimidazole or Na salt thereof |
| US20040010151A1 (en) * | 2002-03-27 | 2004-01-15 | Nina Finkelstein | Lansoprazole polymorphs and processes for preparation thereof |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| ATE508124T1 (en) | 2003-03-24 | 2011-05-15 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING AMORPHIC RABEPRAZOLE SODIUM SALT |
| WO2004113249A2 (en) * | 2003-06-20 | 2004-12-29 | Ch Chemicals (Pty) Ltd | Polyurethane-based cementitious liner |
| AU2004257864A1 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| CA2554271A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| JP2007532677A (en) * | 2004-04-16 | 2007-11-15 | サンタラス インコーポレイティッド | Combination of proton pump inhibitor, buffer, and exercise promoter |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
| CA2787378C (en) | 2004-09-13 | 2015-11-03 | Takeda Pharmaceutical Company Limited | Method for producing lansoprazole crystal |
| JP5124267B2 (en) | 2005-02-25 | 2013-01-23 | 武田薬品工業株式会社 | Granule production method |
| ES2259269B1 (en) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE. |
| AU2006299424A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties |
| KR20080081071A (en) | 2005-12-28 | 2008-09-05 | 다케다 야쿠힌 고교 가부시키가이샤 | Controlled release solid preparation |
| KR100758600B1 (en) * | 2006-01-05 | 2007-09-13 | 주식회사 대웅제약 | Process for preparing Crystalline Form A of Lansoprazole |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| US20100093804A1 (en) * | 2006-12-07 | 2010-04-15 | Hetero Drugs Limited | novel crystalline form of lansoprazole |
| EP2098250B1 (en) | 2006-12-28 | 2016-09-28 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| JP5629581B2 (en) * | 2007-10-12 | 2014-11-19 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | Method for treating digestive disorders independent of food intake |
| EP2222663A1 (en) * | 2007-12-18 | 2010-09-01 | Watson Pharma Private Limited | A process for preparation of stable amorphous r-lansoprazole |
| WO2009088857A1 (en) * | 2007-12-31 | 2009-07-16 | Takeda Pharmaceutical Company Limited | Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole |
| CL2009000547A1 (en) * | 2008-03-10 | 2010-05-07 | Takeda Pharmaceuticals Co | Crystalline form of (r) -2 [[[3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benzimidazole, method of preparation; Pharmaceutical composition and its use for the prophylaxis or treatment of peptic ulcer, gastritis, erosive esophagitis, barret's esophagus, functional dyspepsia, gastric cancer. |
| UY31698A (en) * | 2008-03-11 | 2009-11-10 | Takeda Pharmaceutical | SOLID PREPARATION OF ORAL DISINTEGRATION |
| MX2010010049A (en) * | 2008-03-18 | 2010-10-04 | Reddys Lab Ltd Dr | Dexlansoprazole process and polymorphs. |
| US20090263475A1 (en) * | 2008-04-21 | 2009-10-22 | Nagaraju Manne | Dexlansoprazole compositions |
| AU2009336561A1 (en) | 2008-05-14 | 2010-07-15 | Watson Pharma Private Limited | Stable R-(+)-lansoprazole amine salt and a process for preparing the same |
| JP5295356B2 (en) * | 2008-07-28 | 2013-09-18 | 武田薬品工業株式会社 | Pharmaceutical composition |
| WO2010039885A2 (en) * | 2008-09-30 | 2010-04-08 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of dexlansoprazole |
| IT1391758B1 (en) * | 2008-11-11 | 2012-01-27 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF DEXLANSOPRAZOLO AMORFO |
| WO2010056059A2 (en) * | 2008-11-14 | 2010-05-20 | Hanmi Pharm. Co., Ltd. | Novel crystalline dexlansoprazole and pharmaceutical composition comprising same |
| IT1391776B1 (en) * | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF DEXLANSOPRAZOL |
| IT1392813B1 (en) | 2009-02-06 | 2012-03-23 | Dipharma Francis Srl | CRYSTALLINE FORMS OF DEXLANSOPRAZOLE |
| US20110009637A1 (en) * | 2009-02-10 | 2011-01-13 | Dario Braga | Crystals of Dexlansoprazole |
| WO2011004387A2 (en) * | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
| IT1395118B1 (en) * | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE |
| AU2010319349B2 (en) | 2009-11-12 | 2015-07-16 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| CN102108076B (en) * | 2009-12-23 | 2014-07-23 | 江苏豪森医药集团有限公司 | Method for preparing amorphous dexlansoprazole |
| CA2788147A1 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
| US20110189271A1 (en) * | 2010-02-02 | 2011-08-04 | Vishal Lad | Pharmaceutical formulations of acid-labile drugs |
| WO2011121546A1 (en) | 2010-03-31 | 2011-10-06 | Ranbaxy Laboratories Limited | Salts of dexlansoprazole and their preparation |
| CA2795110C (en) * | 2010-03-31 | 2015-06-09 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
| EP2384746A3 (en) | 2010-05-05 | 2012-03-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dual release oral tablet compositions of dexlansoprazole |
| EP2384745A3 (en) | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of dexlansoprazole |
| EP2384747A3 (en) | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral Tablet Compositions Of Dexlansoprazole |
| WO2012001705A2 (en) | 2010-06-29 | 2012-01-05 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| EP2647381A4 (en) | 2010-12-03 | 2015-12-23 | Takeda Pharmaceutical | Orally disintegrating tablet |
| CN103402500A (en) | 2010-12-27 | 2013-11-20 | 武田药品工业株式会社 | Orally disintegrating tablet |
| EP2663306A4 (en) * | 2011-01-12 | 2014-01-01 | Hetero Research Foundation | Polymorphs of dexlansoprazole salts |
| WO2012104805A1 (en) | 2011-02-01 | 2012-08-09 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
| WO2012111024A1 (en) | 2011-02-18 | 2012-08-23 | Suven Nishtaa Pharma Pvt Ltd | Pharmaceutical compositions of dexlansoprazole |
| AU2012274967A1 (en) * | 2011-06-21 | 2014-01-23 | Sun Pharmaceutical Industries Limited | Process for the preparation of dexlansoprazole |
| CN102875532B (en) * | 2011-07-15 | 2015-05-13 | 上海睿智化学研究有限公司 | (R)-lansoprazole isopropyl amine salt and crystal form and preparation method thereof |
| CN102875530A (en) * | 2011-07-15 | 2013-01-16 | 上海睿智化学研究有限公司 | (R)-lansoprazole tert-butylamine salt and crystal form and preparation method thereof |
| CN102875531B (en) * | 2011-07-15 | 2015-08-19 | 上海睿智化学研究有限公司 | A kind of (R)-lansoprazole anhydrous crystal forms and preparation method thereof |
| CN102234265B (en) * | 2011-08-08 | 2013-11-20 | 天津市汉康医药生物技术有限公司 | Lansoprazole compound |
| AR089032A1 (en) | 2011-11-30 | 2014-07-23 | Takeda Pharmaceutical | DRY COATED TABLET |
| MX2014007239A (en) | 2011-12-16 | 2014-08-08 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis. |
| WO2013140120A1 (en) | 2012-03-22 | 2013-09-26 | Cipla Limited | Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole |
| WO2013179194A1 (en) | 2012-05-31 | 2013-12-05 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline dexlansoprazole |
| CN103709139B (en) * | 2012-10-09 | 2016-12-21 | 上海汇伦生命科技有限公司 | The preparation method of anhydrous R-lansoprazole |
| CN104177333A (en) * | 2013-05-24 | 2014-12-03 | 四川海思科制药有限公司 | (R)-2-[[[3-methyl-4-(2,2,2-trifluoro ethoxy)-2-pyridyl) methyl] sulfinyl]-1 H-benzimidazole with stabile physical and chemical properties |
| CN104650035A (en) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | Dexlansoprazole hemihydrate compound |
| CN103664889B (en) * | 2013-12-19 | 2014-11-19 | 悦康药业集团有限公司 | Lansoprazole compound |
| WO2015155307A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
| EP2933002A1 (en) | 2014-04-11 | 2015-10-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
| CN104844576B (en) * | 2015-04-28 | 2017-03-08 | 山东罗欣药业集团股份有限公司 | A kind of Lansoprazole or Dexlansoprazole crystal-form compound and preparation method thereof |
| CN104829594A (en) * | 2015-05-15 | 2015-08-12 | 苗怡文 | Pharmaceutical lansoprazole compound for treating gastric ulcer |
| CN105017218A (en) * | 2015-07-01 | 2015-11-04 | 合肥安德生制药有限公司 | R-lansoprazole crystal form and preparation method therefor |
| CN104958276A (en) * | 2015-07-30 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Pharmaceutical lansoprazole composition capsule for treating gastric ulcer |
| CN104997738A (en) * | 2015-08-10 | 2015-10-28 | 青岛蓝盛洋医药生物科技有限责任公司 | Medicine lansoprazole compound dry suspension treating gastropathy |
| CN105399728B (en) * | 2015-12-20 | 2017-11-28 | 寿光富康制药有限公司 | A kind of processing method of R-lansoprazole suitable for industrialized production |
| CN108164507A (en) * | 2016-12-07 | 2018-06-15 | 天津药物研究院有限公司 | A kind of R-lansoprazole monocrystalline and its preparation method and application |
| TR201701461A2 (en) | 2017-01-31 | 2018-08-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Enteric Coated Pharmaceutical Compositions of Dexlansoprazole |
| CN106866630B (en) * | 2017-04-01 | 2018-08-07 | 上海华源医药科技发展有限公司 | A kind of preparation method of R-lansoprazole |
| CN107011329A (en) * | 2017-05-05 | 2017-08-04 | 广州大光制药有限公司 | Lansoprazole monohydrate crystal form and its crystallization preparation method |
| CN108794450B (en) * | 2018-07-24 | 2022-08-19 | 浙江恒康药业股份有限公司 | Method for preparing amorphous dexlansoprazole |
| WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (en) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
| DK171989B1 (en) | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles |
| DE4035455A1 (en) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | ENANTIOMER SEPARATION |
| SE504459C2 (en) | 1994-07-15 | 1997-02-17 | Astra Ab | Process for the preparation of substituted sulfoxides |
| GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
| HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
| US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| AU5652698A (en) | 1996-11-12 | 1998-06-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| EP0941102A1 (en) * | 1996-11-22 | 1999-09-15 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid |
| SE510666C2 (en) | 1996-12-20 | 1999-06-14 | Astra Ab | New Crystal Modifications |
| EP1056457A4 (en) | 1998-01-30 | 2006-10-25 | Sepracor Inc | S-lansoprazole compositions and methods |
| WO1999038513A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor Inc. | R-lansoprazole compositions and methods |
| WO1999056698A2 (en) * | 1998-05-06 | 1999-11-11 | Københavns Universitet | Treatment of celiac disease |
| TWI275587B (en) * | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| JP3283252B2 (en) * | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | Crystals of benzimidazole compounds |
| PT1191025E (en) * | 1999-06-30 | 2005-09-30 | Takeda Pharmaceutical | LANSOPRAZOL CRYSTALS |
| CN1117747C (en) * | 2000-06-19 | 2003-08-13 | 中国科学院成都有机化学研究所 | Preparation method of optical purity lansoprazole |
| EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
| ATE508124T1 (en) * | 2003-03-24 | 2011-05-15 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING AMORPHIC RABEPRAZOLE SODIUM SALT |
| WO2006069159A2 (en) * | 2004-12-20 | 2006-06-29 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising amorphous benzimidazole compounds |
| CN101111233A (en) * | 2004-12-23 | 2008-01-23 | 兰贝克赛实验室有限公司 | Stable oral benzimidazole compositions and process of preparation thereof |
| US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
| EP2222663A1 (en) * | 2007-12-18 | 2010-09-01 | Watson Pharma Private Limited | A process for preparation of stable amorphous r-lansoprazole |
-
2000
- 2000-05-30 TW TW089110444A patent/TWI275587B/en not_active IP Right Cessation
- 2000-05-30 TW TW090111098A patent/TWI289557B/en not_active IP Right Cessation
- 2000-06-02 MY MYPI20002497 patent/MY125399A/en unknown
- 2000-06-14 AR ARP000102917A patent/AR031069A1/en not_active Application Discontinuation
- 2000-06-15 ES ES00937235T patent/ES2300265T3/en not_active Expired - Lifetime
- 2000-06-15 NZ NZ515702A patent/NZ515702A/en not_active IP Right Cessation
- 2000-06-15 AU AU52478/00A patent/AU778820B2/en not_active Expired
- 2000-06-15 US US09/674,624 patent/US6462058B1/en not_active Expired - Lifetime
- 2000-06-15 BR BRPI0011674A patent/BRPI0011674B8/en not_active IP Right Cessation
- 2000-06-15 PT PT00937235T patent/PT1129088E/en unknown
- 2000-06-15 KR KR10-2000-7013530A patent/KR100537029B1/en active IP Right Grant
- 2000-06-15 EP EP20100177981 patent/EP2343289A1/en not_active Withdrawn
- 2000-06-15 ES ES08151945T patent/ES2426985T3/en not_active Expired - Lifetime
- 2000-06-15 MX MXPA01012642A patent/MXPA01012642A/en active IP Right Grant
- 2000-06-15 KR KR10-2000-7013512A patent/KR100407847B1/en active IP Right Grant
- 2000-06-15 IL IL14599600A patent/IL145996A0/en unknown
- 2000-06-15 CN CNB008090637A patent/CN1150186C/en not_active Expired - Lifetime
- 2000-06-15 WO PCT/JP2000/003881 patent/WO2004083200A1/en active Application Filing
- 2000-06-15 CA CA2375201A patent/CA2375201C/en not_active Expired - Lifetime
- 2000-06-15 HU HU0201659A patent/HU229067B1/en active Protection Beyond IP Right Term
- 2000-06-15 WO PCT/JP2000/003880 patent/WO2000078745A2/en active Application Filing
- 2000-06-15 DK DK00937235T patent/DK1129088T3/en active
- 2000-06-15 AT AT00937235T patent/ATE391126T1/en active
- 2000-06-15 SI SI200030990T patent/SI1129088T1/en unknown
- 2000-06-15 EP EP08151945.6A patent/EP1977751B1/en not_active Expired - Lifetime
- 2000-06-15 DE DE60038481T patent/DE60038481T2/en not_active Expired - Lifetime
- 2000-06-15 PL PL352193A patent/PL201068B1/en unknown
- 2000-06-15 PT PT81519456T patent/PT1977751E/en unknown
- 2000-06-15 DK DK08151945.6T patent/DK1977751T3/en active
- 2000-06-15 KR KR10-2003-7009783A patent/KR100514204B1/en active IP Right Grant
- 2000-06-15 EP EP00937235A patent/EP1129088B1/en not_active Expired - Lifetime
-
2001
- 2001-09-29 HK HK01106916A patent/HK1038227A1/en not_active IP Right Cessation
- 2001-10-10 ZA ZA200108331A patent/ZA200108331B/en unknown
- 2001-10-17 IL IL145996A patent/IL145996A/en not_active IP Right Cessation
- 2001-12-13 NO NO20016087A patent/NO321168B1/en not_active IP Right Cessation
-
2002
- 2002-09-13 US US10/243,329 patent/US6664276B2/en not_active Expired - Lifetime
-
2003
- 2003-09-04 US US10/655,114 patent/US6939971B2/en not_active Expired - Lifetime
-
2005
- 2005-06-10 US US11/149,903 patent/US7339064B2/en not_active Expired - Lifetime
-
2008
- 2008-01-07 US US12/006,845 patent/US7569697B2/en not_active Expired - Fee Related
- 2008-06-26 CY CY20081100671T patent/CY1110384T1/en unknown
-
2009
- 2009-02-26 US US12/393,409 patent/US7737282B2/en not_active Expired - Fee Related
- 2009-04-01 HK HK09103096.8A patent/HK1123985A1/en not_active IP Right Cessation
-
2010
- 2010-04-30 US US12/771,486 patent/US8030333B2/en not_active Expired - Fee Related
- 2010-12-15 AR ARP100104648A patent/AR079473A2/en not_active Application Discontinuation
-
2011
- 2011-09-01 US US13/223,988 patent/US20110319450A1/en not_active Abandoned
-
2012
- 2012-08-22 US US13/591,992 patent/US8552198B2/en not_active Expired - Fee Related
-
2013
- 2013-09-06 US US14/020,286 patent/US8884019B2/en not_active Expired - Fee Related
- 2013-10-09 CY CY20131100882T patent/CY1114485T1/en unknown
- 2013-11-26 AR ARP130104346A patent/AR093609A2/en unknown
-
2014
- 2014-03-04 BE BE2014C017C patent/BE2014C017I2/fr unknown
- 2014-10-07 US US14/508,651 patent/US9145389B2/en not_active Expired - Fee Related
- 2014-11-12 AR ARP140104252A patent/AR100473A2/en not_active Application Discontinuation
-
2015
- 2015-12-28 AR ARP150104310A patent/AR103295A2/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2375201C (en) | Crystal of (r)-lansoprazole | |
| EP1191025B1 (en) | Crystals of lansoprazole | |
| JP3283252B2 (en) | Crystals of benzimidazole compounds | |
| JP4536905B2 (en) | Crystals of benzimidazole compounds | |
| OA11966A (en) | Benzimidazole compound crystal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20200615 |